Pharmacoperone identification for therapeutic rescue of misfolded mutant proteins
- PMID: 21633718
- PMCID: PMC3103854
- DOI: 10.3389/fendo.2011.00006
Pharmacoperone identification for therapeutic rescue of misfolded mutant proteins
Abstract
G protein-coupled receptors (GPCRs), which includes the gonadotropin releasing hormone (GnRH) receptor (GnRHR), comprises the largest family of validated drug targets-more than half of all approved drugs derive their benefits by selective targeting of GPCRs. Most drugs in this class are either agonists or antagonists of GPCRs and high throughput screens (HTSs) have typically been designed and performed with a view toward identification of such compounds as lead drug candidates. This manuscript presents the case that valuable drugs which effect the trafficking of GPCRs may have been overlooked because pharmacoperones have been selected from existing screens that identify agonists and antagonists. A "gain of activity assay" is proposed; this assay relies on the expression of a mutant of the GnRHR that is known to be rescuable by pharmacoperone drugs, and which is restored to activity in their presence. Accordingly, "hits" are identified by the appearance of activity. The gene for the mutant is under control of tetracycline and may be prevented from being expressed. This is a valuable feature since it allows false positives to be identified. Such drugs will show apparent activity whether or not the mutant is expressed. This assay will enable identification of these drugs from chemical libraries and does not rely on their activity as agonists or antagonists.
Figures




Similar articles
-
Therapeutic rescue of misfolded mutants: validation of primary high throughput screens for identification of pharmacoperone drugs.PLoS One. 2011;6(7):e22784. doi: 10.1371/journal.pone.0022784. Epub 2011 Jul 27. PLoS One. 2011. PMID: 21818389 Free PMC article.
-
A phenotypic high throughput screening assay for the identification of pharmacoperones for the gonadotropin releasing hormone receptor.Assay Drug Dev Technol. 2014 May;12(4):238-46. doi: 10.1089/adt.2014.576. Assay Drug Dev Technol. 2014. PMID: 24831790 Free PMC article.
-
Therapeutic rescue of misfolded/mistrafficked mutants: automation-friendly high-throughput assays for identification of pharmacoperone drugs of GPCRs.Methods Enzymol. 2013;521:3-16. doi: 10.1016/B978-0-12-391862-8.00001-6. Methods Enzymol. 2013. PMID: 23351731
-
Pharmacoperones for Misfolded Gonadotropin Receptors.Handb Exp Pharmacol. 2018;245:111-134. doi: 10.1007/164_2017_64. Handb Exp Pharmacol. 2018. PMID: 29043503 Review.
-
Trafficking of G-protein-coupled receptors to the plasma membrane: insights for pharmacoperone drugs.Trends Endocrinol Metab. 2010 Mar;21(3):190-7. doi: 10.1016/j.tem.2009.11.003. Epub 2009 Dec 11. Trends Endocrinol Metab. 2010. PMID: 20005736 Free PMC article. Review.
Cited by
-
Pharmacological chaperoning: a primer on mechanism and pharmacology.Pharmacol Res. 2014 May;83:10-9. doi: 10.1016/j.phrs.2014.01.005. Epub 2014 Feb 14. Pharmacol Res. 2014. PMID: 24530489 Free PMC article. Review.
-
Targeting trafficking as a therapeutic avenue for misfolded GPCRs leading to endocrine diseases.Front Endocrinol (Lausanne). 2022 Aug 25;13:934685. doi: 10.3389/fendo.2022.934685. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 36093106 Free PMC article. Review.
-
Mutations in G protein-coupled receptors that impact receptor trafficking and reproductive function.Mol Cell Endocrinol. 2014 Jan 25;382(1):411-423. doi: 10.1016/j.mce.2013.06.024. Epub 2013 Jun 24. Mol Cell Endocrinol. 2014. PMID: 23806559 Free PMC article. Review.
-
Misfolded G Protein-Coupled Receptors and Endocrine Disease. Molecular Mechanisms and Therapeutic Prospects.Int J Mol Sci. 2021 Nov 15;22(22):12329. doi: 10.3390/ijms222212329. Int J Mol Sci. 2021. PMID: 34830210 Free PMC article. Review.
-
Pharmacoperones as Novel Therapeutics for Diverse Protein Conformational Diseases.Physiol Rev. 2018 Apr 1;98(2):697-725. doi: 10.1152/physrev.00029.2016. Physiol Rev. 2018. PMID: 29442594 Free PMC article. Review.
References
-
- Amaral M. D. (2006). Therapy through chaperones: sense or antisense? Cystic fibrosis as a model disease. J. Inherit. Metab. Dis. 29, 477–487 - PubMed
-
- Andersson H., D'Antona A. M., Kendall D. A., Von Heijne G., Chin C. N. (2003). Membrane assembly of the cannabinoid receptor 1: impact of a long N-terminal tail. Mol. Pharmacol. 64, 570–577 - PubMed
-
- Ashton W. T., Sisco R. M., Kieczykowski G. R., Yang Y. T., Yudkovitz J. B., Cui J., Mount G. R., Ren R. N., Wu T. J., Shen X., Lyons K. A., Mao A. H., Carlin J. R., Karanam B. V., Vincent S. H., Cheng K., Goulet M. T. (2001). Orally bioavailable, indole-based nonpeptide GnRH receptor antagonists with high potency and functional activity. Bioorg. Med. Chem. Lett. 11, 2597–2602 - PubMed
-
- Bellotti V., Nuvolone M., Giorgetti S., Obici L., Palladini G., Russo P., Lavatelli F., Perfetti V., Merlini G. (2007). The workings of the amyloid diseases. Ann. Med. 39, 200–207 - PubMed
-
- Benedek G. B., Pande J., Thurston G. M., Clark J. I. (1999). Theoretical and experimental basis for the inhibition of cataract. Prog. Retin. Eye Res. 18, 391–402 - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources